PharmAkea: Celgene-Seeded PharmAkea Sells Last Fibrotic Drug Candidate to Galecto

When a group of scientists from Amira Pharmaceuticals wanted to start a new biotech after the company's 2011 acquisition by Bristol-Myers Squibb, Celgene provided seed funding. Eventually Celgene kicked in $35 million more for a research collaboration, an equity stake, and an exclusive option to acquire the startup, PharmAkea Therapeutics. But the partnership fizzled, and [...]